Thanks Bocxman. Sorry about being so thick about this. The company's PRs haven't been completely clear on these details, so I really appreciate your explanation!
Of course, it's just plain weird that the share price isn't MUCH higher right now given that the timeline to commercialization is so short. I suspect this is because, as you've said, the market is waiting for independent validation of the specificity/sensitivity numbers from Abbott or elsewhere.
It seems to me that there really isn't a lot of technology risk in this stock. The numbers from the internal studies have been so consistently outstanding that outright failure to replicate the results in a larger cohort is very unlikely. We are left then with the probability of either magnificent results (in which case the SP should go berserk), or accuracy numbers that are good but not quite as high as the 90 per cent rates from the internal studies (in which case we should still get a huge increase in the stock price).
Correct me if I'm wrong, but it's a win-win situation, and the current price makes the stock an outstanding opportunity...
Good luck to everyone...
News 
Market Data 
Discover 
